M&A Corner
Revolutionizing Healthcare | Mass General Brigham Teams with AvoMD11 Mar 2024
Mass General Brigham partners with AvoMD to enhance rapid response care workflows, integrating digital tools into clinical processes via EHR... Continue Reading
|
Telix Boosts Isotope Production | Acquires ARTMS Technology11 Mar 2024
Telix Pharmaceuticals Limited is acquiring ARTMS Inc., a leading radioisotope production technology firm. The deal includes ARTMS’ advanced cyclotron-based isotope... Continue Reading
|
Ness Therapeutics Acquisition | Elevating Cancer Immunotherapy Potentials11 Mar 2024
Eilean Therapeutics LLC has acquired Ness Therapeutics Inc in an equity transaction, gaining access to their leading PTPN2 inhibitors for... Continue Reading
|
Salvo Health Raises $5M to Transform GI Healthcare07 Mar 2024
Salvo Health, a digital GI care startup, secures $5M in Seed Prime funding led by City Light Capital and Human... Continue Reading
|
Moxe Health’s $25M Boost from Trinity Reshapes Data Exchange07 Mar 2024
Moxe Health secures $25M from Trinity Capital for its healthcare data exchange tools. Their convergence product enables payers to input... Continue Reading
|
Absci’s $75M Offering: Powering Drug Innovation and Growth07 Mar 2024
Absci Corporation (Nasdaq: ABSI) announces a $75 million public offering to support internal drug development, enhance their Integrated Drug Creation™... Continue Reading
|
Alamar Biosciences: $128M Boost for Precision Proteomics07 Mar 2024
Alamar Biosciences secures $128M, led by Sands Capital, for their precision proteomics platform. Series C funding, totaling nearly $250M, will... Continue Reading
|
Recce Pharmaceuticals and MCRI: Fighting Infectious Diseases Together07 Mar 2024
Recce Pharmaceuticals extends collaboration with Murdoch Children’s Research Institute, focusing on their Anti-Infective Research (AIR) Unit. Led by Dr. Sohinee... Continue Reading
|
Intelligent Bio Solutions and Cliantha Research Collaborate07 Mar 2024
Intelligent Bio Solutions Inc. partners with Cliantha Research for a pharmacokinetic study as part of FDA 510(k) pathway. The study,... Continue Reading
|
Dyadic-Rabian Alliance: Revolutionizing Rabies Prevention Worldwide07 Mar 2024
Dyadic International partners with Rabian BV to develop affordable rabies prophylactics using its C1 protein production platform. The collaboration aims... Continue Reading
|